Liquid Biopsy Testing Detects Recurrence in High-Risk NSCLC

Ariela Katz
Published: Thursday, Apr 13, 2017
Chimbu Chinniah

Chimbu Chinniah

The results of a recent prospective study demonstrate that circulating tumor cells (CTCs) can reveal disease recurrence an average of 6 months prior to conventional imaging in patients with locally advanced non–small cell lung cancer (NSCLC), findings that may help support the use of liquid biopsies to monitor high- risk patients in conjunction with screening.1


Table. How the Study Was Conducted1

“High levels of telomerase are found in almost all cancer cells, but almost no normal cells, with the exception of rare stem cells. Consequently, it’s a specific marker of live cancer cells,” Chinniah explained during a press briefing at the symposium, which the American Society for Radiation Oncology sponsored March 16 to 18 in San Francisco.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication